Introduction
Beacon Biosignals is a Boston company founded in 2019 that combines FDA-cleared wearable electroencephalography technology with artificial intelligence to capture and analyze brain data for clinical trials, diagnostics, and sleep medicine. Jacob Donoghue, MD, PhD, serves as chief executive officer and co-founder per Beacon’s about page — a neurologist-scientist whose background spans Harvard Medical School and MIT neuroscience research.
On April 6, 2026, Beacon announced an extension to its Series B financing bringing the round to $97 million and cumulative company funding to more than $132 million, with new investors including JSL Health, Palo Santo VC, Kicker Ventures, and Samsung Next. Brel cites this milestone because Beacon sits at the intersection of pharma trial endpoints and regulated wearable AI — a category where objective brain measures could replace subjective CNS rating scales if scaled reliably.
Prior Beacon releases document FDA authorization of predetermined change control plans for its sleep wearable and multi-year Takeda collaborations on narcolepsy neurobiomarkers — context for the April 2026 financing as scale capital rather than early proof-of-concept funding alone.
What the company does
Beacon’s platform pairs clinical-grade at-home EEG hardware with AI analytics that quantify sleep architecture, epileptiform activity, and other neural biomarkers. The company’s Waveband headband — renamed from Dreem 3S while retaining FDA 510(k) clearance per Beacon news materials — supports predetermined change control plans allowing algorithm updates under FDA oversight. Beacon serves biopharma partners running CNS and sleep trials needing continuous, objective EEG endpoints outside sleep-lab environments.
Following the April 2025 acquisition of CleveMed, Beacon expanded home sleep testing services and commercial sleep diagnostics expertise — integrating hardware, services, and analytics into one neurotechnology stack rather than selling algorithms alone.
Who it serves
Beacon sells to biopharmaceutical R&D teams in neurology, psychiatry, and sleep therapeutics — named partners include Takeda in multi-year narcolepsy and neurobiomarker collaborations and Harmony Biosciences in hypersomnia endpoint development per Beacon news releases. Clinical sleep programs and research hospitals use Beacon tools where polysomnography capacity constraints limit trial enrollment and real-world monitoring.
Donoghue’s quoted vision — making brain health measurable, scalable, and actionable — targets buyers frustrated by subjective trial endpoints in conditions where EEG phenotypes may provide earlier signal of drug effect.
Beacon’s April 2025 CleveMed acquisition brought home sleep testing operations expertise under one roof — relevant for sponsors who need both wearable hardware and service-layer logistics for decentralized trial arms, not algorithm licenses alone.
Company background
Donoghue co-founded Beacon in 2019 in Boston with CTO and co-founder Jarrett Revels, building on machine learning and neuroscience research. The leadership team includes chief clinical officer Matt Alkaitis, MD, PhD, who maintains part-time internal medicine practice at Stanford, and veterans from Apple sleep algorithms, GE HealthCare regulatory affairs, and CleveMed sleep diagnostics per the about page. Beacon’s investor syndicate includes Innoviva, GV, General Catalyst, Casdin Capital, and others cited in the April 2026 financing release.
Product and AI capabilities
Beacon applies deep learning to sleep EEG signals captured by wearable headbands, producing biomarkers pharma teams embed as exploratory or secondary endpoints in trial protocols. FDA authorization of predetermined change control plans for its sleep wearable — referenced in prior Beacon news — matters for multi-year trial contracts where frozen algorithms otherwise prevent model improvements mid-study.
Beacon’s HEADFIRST pediatric developmental disorders trial and American Epilepsy Society sleep EEG presentations illustrate how the company positions AI analytics as infrastructure spanning trial operations and eventual diagnostic products.
Key developments
2019: Beacon Biosignals founded in Boston. December 2024: FDA authorizes Dreem 3S with predetermined change control plan for sleep wearable. April 21, 2025: CleveMed acquisition completed. November 2025: Takeda collaboration expansion for narcolepsy diagnosis. April 6, 2026: Series B extended to $97 million; cumulative funding exceeds $132 million.
Why it matters
Beacon matters because CNS drug development suffers from noisy subjective endpoints — wearable EEG plus AI offers a path to continuous, objective brain measurements if pharma sponsors trust regulatory and analytical validation. The April 2026 financing signals investor conviction in that infrastructure play. Compare with point-of-care EEG device maker Ceribell in acute seizure detection and digital health analytics vendors serving different brain-data modalities.
Palo Santo investor Daniel Goldberg’s April 2026 quote links Beacon’s EEG platform to emerging psychiatric therapeutics including psychedelics — endpoint objectivity becomes more urgent when subjective patient reports dominate legacy trial designs in those categories.
Sector context
Beacon Biosignals belongs in Brel’s AI in healthcare coverage under neurotechnology and clinical-trial AI, related to acute EEG vendor Ceribell and TechBio discovery platforms such as Recursion Pharmaceuticals. Cardiology AI vendors like Anumana apply similar ECG-AI paradigms to a different organ system and reimbursement pathway.
Waveband rename from Dreem 3S per Beacon news reflects brand consolidation after CleveMed acquisition — buyers evaluating sleep EEG vendors should confirm regulatory labels and predetermined change control documentation under current product names.
Sources and references
Beacon Series B extension news (April 6, 2026) and about page with leadership roster.
- Beacon Biosignals — Series B extension (beacon.bio, April 6, 2026)
- Beacon Biosignals — About (beacon.bio)
Reviewed July 10, 2026. Jacob Donoghue, MD, PhD, is CEO and co-founder. Founded 2019 in Boston. Confidence: High.